Related Resources for this page:
- Biological Pathways
- Therapeutic Targets
- Research Education
- Clinical Trials
- Cancer Biomarkers
- Future Directions
- Antibody-Drug conjugates
- Summary
- A brief history of ADCs
- Cancer effects
- Current research in ADCs
- Cytotoxic agent
- Emerging therapeutic options
- Emerging therapeutic options
- HER2
- VEGF expression in gastric cancer
- HER ligands
- HER pathways slide decks and videos
- Glossary
- Receptor activation
- Dimerization
- HER Signaling
- Overview
- HER1/EGFR evaluation
- HER1/EGFR and prognosis
- HER1/EGFR as a therapeutic target
- Summary
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER2 dysregulation
- HER2:HER3 dimer
- HER2 and prognosis
- HER2 detection methods
- HER2 as a therapeutic target
- HER2 in breast cancer
- Summary
- HER2 in ovarian cancer
- HER3 dysregulation
- HER3
- HER3 evaluation
- HER3 as a therapeutic target
- HER3 in breast cancer
- HER3 in ovarian cancer
- HER4
- High VEGF expression
- How are ADCs designed to work?
- VEGF and prognosis in multiple myeloma
- Glossary
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Monoclonal antibody
- Multimedia Resources
- Receptor-Mediated Endocytosis
- Research ADCs
- Research MET
- VEGF, MVD, and metastases in gastric carcinoma
- Stable linker
- HER receptors
- Summary
- Targeting cancers with ADCs
- Therapeutic potential of HER pathways
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- What are ADCs?
- What is Met?
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Emerging therapeutic options
- Emerging therapeutic options
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- VEGF, MVD, and metastases in gastric carcinoma
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Non-Antibody Biologics
- Apoptosis
- VEGF expression in gastric cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- VEGF, MVD, and metastases in gastric carcinoma
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Targeted Small Molecules
- Summary
- Cancer effects
- Apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- HER2
- VEGF expression in gastric cancer
- Gastric Cancer
- HER ligands
- HER pathways slide decks and videos
- Glossary
- Receptor activation
- Dimerization
- Overview
- HER1/EGFR evaluation
- HER1/EGFR and prognosis
- HER1/EGFR as a therapeutic target
- Summary
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER2 dysregulation
- HER2:HER3 dimer
- HER2 and prognosis
- HER2 detection methods
- HER2 as a therapeutic target
- HER2 in breast cancer
- Summary
- HER2 in ovarian cancer
- HER3 dysregulation
- HER3
- HER3 evaluation
- HER3 as a therapeutic target
- HER3 in breast cancer
- HER3 in ovarian cancer
- HER4
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- Glossary
- VEGF expression and liver metastases
- MAPK Signaling
- Melanoma
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Other Tumor Types
- Research MET
- VEGF, MVD, and metastases in gastric carcinoma
- HER receptors
- Summary
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- What is Met?
- Traditional Monoclonal Antibodies
- Summary
- Anti-EGFL7
- B-cell Surface Proteins
- Cancer effects
- Glossary
- Emerging therapeutic options
- Emerging therapeutic options
- HER2
- VEGF expression in gastric cancer
- Gastric Cancer
- HER ligands
- HER pathways slide decks and videos
- Glossary
- Receptor activation
- Dimerization
- HER Signaling
- Overview
- HER1/EGFR evaluation
- HER1/EGFR and prognosis
- HER1/EGFR as a therapeutic target
- Summary
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER2 dysregulation
- HER2:HER3 dimer
- HER2 and prognosis
- HER2 detection methods
- HER2 as a therapeutic target
- HER2 in breast cancer
- Summary
- HER2 in ovarian cancer
- HER3 dysregulation
- HER3
- HER3 evaluation
- HER3 as a therapeutic target
- HER3 in breast cancer
- HER3 in ovarian cancer
- HER4
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- Melanoma
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Research MET
- VEGF, MVD, and metastases in gastric carcinoma
- HER receptors
- Summary
- Angiogenic Signaling
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- What is Met?
- Antibody-Drug conjugates
Pancreatic Cancer
Disease Information
Genentech BioOncology is dedicated to advancing the science of pancreatic cancer therapy through comprehensive research programs and education. Pancreatic cancer is the uncontrolled growth of cancerous cells formed in the tissues of the pancreas. The cancer may develop in the head, body, or tail of the pancreas.1
- Most pancreatic tumors originate in the exocrine duct cells or acinar cells. Ninety-five percent of exocrine pancreatic cancers are adenocarcinomas1
- Endocrine and ampullary cancers are 2 other less common types of pancreatic cancer1
- Tumors that begin in the islet cells are referred to as endocrine tumors
- Ampullary tumors develop in the ampulla of Vater — located where the bile and pancreatic ducts empty into the small intestine
Pancreatic Cancer Demographics
- In 2010, over 43,000 people in the United States were diagnosed with pancreatic cancer and more than 36,000 died of the disease2
- The incidence and death rate for pancreatic cancer has been rising slightly in women for several years2
Pancreatic Cancer Epidemiology
- Smoking, family history of pancreatic cancer, personal history of pancreatitis, diabetes, and obesity can contribute to the development of pancreatic cancer2
- Smoking doubles a person’s risk of developing pancreatic cancer2
- Despite significant advances in the treatment of many other human tumors, the 5-year survival rate for persons diagnosed with pancreatic cancer remains at about 6%2
- For those patients with localized disease, the 5-year relative survival rate is about 20%2
Pancreatic tumors often develop without overt symptoms. Some conditions such as glucose intolerance, jaundice, or pain in the upper abdomen may indicate pancreatic cancer, but it often goes undiagnosed until the cancer is quite advanced.1,2 There are currently no methods for early detection of pancreatic cancer.1,2
Other links to pancreatic cancer disease information
These links give a sampling of other sites offering information on pancreatic cancer, which you may find useful in your practice.
- National Cancer Institute at National Institutes of Health, Pancreatic Cancer
- ASCO Cancer Portals - Gastrointestinal Cancer
- Cancer Facts & Figures
Unless otherwise indicated, Genentech, Inc. is neither affiliated with nor endorses any of the organizations listed.
References:
- 1.
- American Cancer Society. Pancreatic cancer. www.cancer.org/Cancer/PancreaticCancer/DetailedGuide/
pancreatic-cancer-what-is-cancer. Accessed April 14, 2011. - 2.
- American Cancer Society. Cancer Facts & Figures 2010. www.cancer.org/acs/groups/content/@epidemiologysurveilance/
documents/document/acspc-026238.pdf. Accessed April 14, 2011.